NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 29, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.

PRNewsWire • May 29, 2026

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. a global pharmaceutical company, today announced the launch of its generic Semaglutide Injection in Canada.

Business Wire • May 16, 2026

Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Dr. Reddy's Laboratories NYSE: RDY reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter.

MarketBeat • May 14, 2026

Dr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock Down

RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.

Zacks Investment Research • May 13, 2026

Indian drugmaker Dr Reddy's posts quarterly profit slump

Indian drugmaker Dr Reddy's ​reported an 86% ‌slump in quarterly profit on Tuesday, ​hurt by pricing ​pressure and increasing competition ⁠in its ​key U.S. market.

Reuters • May 12, 2026

Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript

Seeking Alpha • May 12, 2026

Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection.

Business Wire • Apr 29, 2026

Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic

The country is the first in the G7 forum to approve a generic version of the massively popular GLP-1 diabetes treatment.

WSJ • Apr 29, 2026

AMPH vs. RDY: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Generic Drugs sector have probably already heard of Amphastar Pharmaceuticals (AMPH) and Doctor Reddy's (RDY). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Apr 29, 2026

3 Generic Drug Stocks to Watch Despite Industry Headwinds

Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.

Zacks Investment Research • Mar 4, 2026